Adnan YÖNEY, Emine ÇAKIR, Zümrüt BAHAT, Ozan Cem GÜLER, Emine CANYILMAZ, Mustafa KANDAZ

Prognostic Value of Pretreatment HER2 Status in Gastric Cancer Patients Treated with Postoperative Chemoradiotherapy

Our purpose was to evaluate the prognostic or predictive importance of HER2 status in gastric cancerpatients treated with postoperative chemoradiotherapy.METHODSWe retrospectively analyzed the records of 49 gastric cancer patients treated with curative intent betweenApril 2012 and January 2017; we also assessed the impact of HER2 status on prognosis and treatmentoutcomes.RESULTSDuring a median follow-up period of 14.6 months (range, 4.0-56.97 months), two patients (4%) had localrecurrence and 21 patients (43%) developed distant metastasis. We found no statistically significant differencein metastasis frequency rates between HER2 negative (-) and positive (+) patients. The medianoverall survival (OS) and disease-free survival (DFS) for the whole group were 24.9 and 24.2 months,respectively. Although there was no significant difference in OS and DFS according to HER2 status, therewas a negative trend in OS (p=0.451) and DFS (p=0.633) in HER2 (+) patients.CONCLUSIONAlthough our study did not demonstrate any statistically significant importance of HER2 status in gastriccancer patients treated with postoperative chemoradiotherapy, the median OS of 13 months in HER2(+) patients and 24.9 months for HER2 (-) patients warranted randomized trials with larger cohorts.

PDF

___

1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin 2015;65(2):87-108.
2. İzmirli M, Kilic K, Yilmazer G, Nart M. A retrospective analysis of prognostic factors and treatment results of gastric adenocarcinomas treated with postoperative chemoradiotherapy. Turk J Oncol 2014;29(4):137-47.
3. Sökücü N, Balık E. Mide Kanseri Tedavisinde Güncel Algoritma. Turkiye Klinikleri J Gen Surg-Special Topics 2013;6(3):39-47.
4. Smalley SR, Benedetti JK, Haller DG, Hundahl SA, Estes NC, Ajani JA, et al. Updated analysis of SWOGdirected intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection. J Clin Oncol 2012;30(19):2327-33.
5. Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M, Nashimoto A, et al; ACTS-GC Group. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 2007;357(18):1810-20.
6. Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, et al; MAGIC Trial Participants. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006;355(1):11-20.
7. Baselga J, Tripathy D, Mendelsohn J, Baughman S, Benz CC, Dantis L, et al. Phase II study of weekly intravenous trastuzumab (Herceptin) in patients with HER2/neuoverexpressing metastatic breast cancer. Semin Oncol 1999;26(4 Suppl 12):78-83.
8. Rayson D, Lutes S, Walsh G, Sellon M, Colwell B, Dorreen M, et al. Trastuzumab beyond progression for HER2 positive metastatic breast cancer: progressionfree survival on first-line therapy predicts overall survival impact. Breast J 2014;20(4):408-13.
9. Maresch J, Schoppmann SF, Thallinger CM, Zielinski CC, Hejna M. Her-2/neu gene amplification and over-expression in stomach and esophageal adenocarcinoma: from pathology to treatment. Crit Rev Oncol Hematol 2012;82(3):310-22.
10.Pak Y. Radyoterapinin mide kanseri tedavisindeki yeri. Turkiye Klinikleri J Surgery 2000;5(4):196-202.
11.Oruc A, Karabulut Gül S, Mayadaglı A. Radiotherapy of stomach cancer. Turkiye Klinikleri J Med OncolSpecial Topics 2012;5(3):30-6.
12.Macdonald JS, Smalley SR, Benedetti J, Hundahl SA, Estes NC, Stemmermann GN, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001;345(10):725-30.
13.Apicella M, Corso S, Giordano S. Targeted therapies for gastric cancer: failures and hopes from clinical trials. Oncotarget 2017;8(34):57654-69.
14.Gravalos C, Jimeno A. HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann Oncol 2008;19(9):1523-9.
15.Bang YJ. Advances in the management of HER2-positive advanced gastric and gastroesophageal junction cancer. J Clin Gastroenterol 2012;46(8):637-48.
16.Terashima M, Kitada K, Ochiai A, Ichikawa W, Kurahashi I, Sakuramoto S, et al; ACTS-GC Group. Impact of expression of human epidermal growth factor receptors EGFR and ERBB2 on survival in stage II/III gastric cancer. Clin Cancer Res 2012;18(21):5992- 6000.
17.Shen GS, Zhao JD, Zhao JH, Ma XF, Du F, Kan J, et al. Association of HER2 status with prognosis in gastric cancer patients undergoing R0 resection: A large-scale multicenter study in China. World J Gastroenterol 2016;22(23):5406-14. Turk J Oncol 2017;32(3):89-94 doi: 10.5505/tjo.2017.1598
18.Gordon MA, Gundacker HM, Benedetti J, Macdonald JS, Baranda JC, Levin WJ, et al. Assessment of HER2 gene amplification in adenocarcinomas of the stomach or gastroesophageal junction in the INT-0116/ SWOG9008 clinical trial. Ann Oncol 2013;24(7):1754- 61.
19.Okines AF, Thompson LC, Cunningham D, Wotherspoon A, Reis-Filho JS, Langley RE, et al. Effect of HER2 on prognosis and benefit from peri-operative chemotherapy in early oesophago-gastric adenocarcinoma in the MAGIC trial. Ann Oncol 2013;24(5):1253-61.
20.Pietras RJ, Poen JC, Gallardo D, Wongvipat PN, Lee HJ, Slamon DJ. Monoclonal antibody to HER-2/neureceptor modulates repair of radiation-induced DNA damage and enhances radiosensitivity of human breast cancer cells overexpressing this oncogene. Cancer Res 1999;59(6):1347-55.
21.Jørgensen JT, Hersom M. HER2 as a Prognostic Marker in Gastric Cancer-A Systematic Analysis of Data from the Literature. J Cancer 2012;3:137-44.
22.Li HK, Morokoshi Y, Nagatsu K, Kamada T, Hasegawa S. Locoregional therapy with ?-emitting trastuzumab against peritoneal metastasis of human epidermal growth factor receptor 2-positive gastric cancer in mice. Cancer Sci 2017;108(8):1648-56.